Abstract

Serum levels of osteocalcin (OC), a bone matrix non-collagenous protein secreted by osteoblasts, are correlated with pathological bone remodeling such as the bone metastasis of cancer, as well as physiological bone turnover. The pathological roles in prostate cancer growth of the two existing types of serum OC, γ-carboxylated (GlaOC) and lower- (or un-) carboxylated (GluOC), have not yet been discriminatively examined. In the present study, we demonstrate that normal prostate epithelial cell growth was promoted by both types of OC, while growth of cancer cells in the prostate was accelerated by GlaOC but suppressed by GluOC. We suggest that OC regulates prostate cancer growth depending on the γ-carboxylation, in part by triggering reduced phosphorylation of receptor tyrosine kinases.

Key words: osteocalcin, prostate cancer

Introduction

Prostate cancer is one of the most prevalent malignant diseases of men worldwide, and it remains a challenge to distinguish and prevent lethal metastatic prostate cancers, which escape standard therapeutic intervention. Bone is a preferred organ for the metastasis of prostate cancer [1-4], and the metastasis to bone is associated with increased osteoblast activity [4]. In fact, the production of OC by osteoblasts is well correlated with the metastasis of prostate cancer progression [1], and therefore high levels of OC in the serum are assumed to be a metastatic marker of prostate cancer [2,3]. Furthermore, OC has been reported to promote prostate cancer progression [5], but previous studies did not discriminate between the two existing OC types, GlaOC and GluOC. GluOC but not GlaOC has recently been reported to improve glucose metabolism [6-10]. These findings indicate that each form of OC plays a different role depending on the pathophysiological conditions. Therefore, it is important to examine which form of OC is involved in prostate cancer progression. In the present study, GlaOC and GluOC were separately examined to determine their roles in prostate cancer cell growth.

Materials and Methods

Materials

Recombinant GluOC was prepared as described previously [7]. GlaOC was purchased from AnaSpec (Fremont, CA, USA).

Cells

A human prostate cancer cell line (PC-3) and normal prostate epithelial (ProEpi) cells were purchased from ATCC (Rockville, MD, USA) and...
Lonza (Basel, Switzerland), respectively. A human prostate carcinoma cell line, PPC-1, was kindly provided by Dr. J.Y. Bahk (Gyeongsang National University, Korea). The two prostate cancer cell lines and ProEpi cells were maintained in Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum (Thermo Fisher Scientific, Waltham, MA, USA) and PrEGM™ Prostate Epithelial Cell Growth Medium BulletKit™ (Lonza), respectively. All cells were cultured at 37°C in humidified air containing 5% CO₂.

**Measurement of cell viability**

Cell viability was determined with a WST-8 assay (Cell Count Reagent SF; Nakalai Tesque, Kyoto, Japan) and a BrdU uptake assay (BrdU Cell Proliferation ELISA Kit; Exalpha Biologicals, Shirley, MA, USA). Each cell seeding density was optimized before experiments. Prior to assays, cells were treated with vehicle, GluOC or GlaOC (1, 10, 100 ng/ml), in 96-well culture plates in 100 μl for 24 h or 48 h, after preculture in each maintenance medium for 24 h.

**Results and Discussion**

**Effects of GlaOC and GluOC on cell viability in human prostate cells**

GlaOC at concentration of 1-100 ng/ml dose-dependently promoted the viability of the human prostate cancer cell lines PC-3 and PPC-1 in a WST-8 assay for 24 h, except for PC-3 cells at 100 ng/ml at 24 h (Fig 1A). We also assayed WST-8 for 48 h; more promotion than that for 24 h was observed, except for PPC1 cell line. In contrast, GluOC at the same concentrations inhibited viability of these two cell lines in a similar manner as in the WST-8 assay, while the effect of GlaOC was not significantly manifested in this assay for unknown reasons (Fig 1AB). In contrast, both GlaOC and GluOC promoted the growth of the ProEpi cell line of
normal prostate epithelial cells, as assessed by WST-8 (at 24 h and 48 h) and BrdU assays (at 24 h) (Fig 1AB). These results indicate that GlaOC and GluOC have stimulatory and inhibitory effects on prostate cancer cell growth, respectively, but that normal prostate epithelial cells respond in a similar manner to both forms.

**Regulation of the phosphorylation levels of RTKs by GlaOC and GluOC in human prostate cells**

Receptor tyrosine kinases (RTKs), a family of cell surface receptors for growth factors, mediate an initial signaling for cell proliferation [11]. We therefore assayed phospho-RTKs arrays using PPC-1 as cancer cells and ProEpi as normal cells to elucidate the mechanism by which GlaOC or GluOC affects cell growth. GlaOC enhanced the phosphorylation levels of nine RTKs, including FGFR1 (fibroblast growth factor receptor 1) [12], EphA4 (ephrin receptor A4) [13], EphA7 [14], EphA10 [15], EphB2 [16], EphB4 [17], EphR (ephrin receptor) [18], ALK (anaplastic lymphoma kinase) [19], and RYK [20] (Fig. 2A), which are all closely related to prostate cancer progression in PPC-1 cells [12-20]. In contrast, GluOC did not enhance any RTKs, but rather reduced phosphorylation levels of fifteen RTKs, including FGFR1 [12], EphA4 [13], EphA7 [14], EphA10 [15], EphB4 [17], EphR [18], ALK [19], RYK [20], HGFR (hepatocyte growth factor receptor) [21], FGFR3 [22], c-Ret [23], Ror1 [24], Ror2 [24], Axl [25], and EphA2 [13] (Fig. 2A), whose expression or activation are also closely related to prostate cancer progression [12-15,17-25].
These results indicate that GlaOC promotes prostate cancer cell proliferation through the activation of nine RTKs, although it remains unclear whether GlaOC is a direct ligand for those RTKs. The mechanisms for GlaOC effect are currently unknown because the receptors for GlaOC and the signaling cascade have not yet been identified, but the tyrosine kinases are involved in the growth promotion since LY294002, an inhibitor for PI3 kinase and U0126, an inhibitor for MEK1/2 kinase, down-stream kinases after tyrosine kinase activation completely blocked the growth promotion by GlaOC (data not shown). On the contrary, GluOC is recognized by a tentative receptor, GPRC6A, followed by activation of cAMP production and protein kinase A [10], which might be implicated in the inhibition of several tyrosine kinases. We here suggest that GluOC could be a potential therapeutic agent against cancer, as it might inhibit the RTK-related signal transduction that is constitutively active in malignant cells [11].

Phosphorylation of RTKs using ProEpi cells, normal cells displayed different patterns, except for EphA10 (Fig. 2B). The most distinctive feature was that GluOC triggered increased phosphorylation of six RTKs in ProEpi cells, FGFR1 [12], EphB2 [16], EphR [18], ALK [19], RYK [20], and PDGFRα (platelet-derived growth factor receptor alpha) [26], which may be correlated with the proliferative activity triggered by GluOC in normal cells. On the other hand, GlaOC also triggered increased...
phosphorylation of the same RTKs as GluOC, including FGFR1 [12], EphR [18], ALK [19], and RYK [20]. Additionally, GlaoCA promoted the phosphorylation of additional nine RTKs, EphA10 [15], EphB4 [17], EphB6 [27], FGFR2a [28], FGFR3 [22], DDR1 (discoidin domain receptor 1) [29], VEGFR3 [30], Tie-2 [31], and TrkA [32] (Fig 2B). The mechanisms for GluOC to promote the growth in normal cells, likely by activation of tyrosine kinases are currently unknown.

These findings indicate that serum OC may contribute to prostate tissue homeostasis by regulating the RTK phosphorylation status, and that GlaoCA and GluOC are discriminatively involved in prostate cell proliferation. In order to advance future clinical studies, GlaoCA and GluOC have to be considered discriminatively.

Acknowledgements

This work was supported by the Japan Society for the Promotion of Science (KAKENHI grants 24229009 to M.H., 26861554 and 16K11496 to T.K.-Y., and 26861553 and 16K20421 to A.M.).

Competing Interests

The authors have declared that no competing interest exists.

References

1. Gardner TA, Lee SJ, Lee SD, Li X, Shirakawa T, Kwon DD, Park RY, Ahn KY, Jung C. Differential expression of osteocalcin during the metastatic progression of prostate cancer. Oncol Rep. 2009; 21:903-908.

2. Koizumi M, Yonese J, Fuki J, Opata E. Metabolic gaps in bone formation may be a novel marker to monitor the osteous metastasis of prostate cancer. J Urol. 2010; 183:1863-1866.

3. Nimpusch K, Rohrmann S, Nieters A, Linseisen J. Serum undercarboxylated osteocalcin as biomarker of vitamin K intake and risk of prostate cancer: a nested case-control study in the Heidelberg cohort of the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2009; 18:49-56.

4. Fagberg Thulin M, Irenback K, Dambe J, Welén K. Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies. Clin Exp Metastasis. 2014; 31:269-283.

5. Pi M and Quales LD. GPRC6A regulates prostate cancer progression. Prostate. 2012; 72:399-409.

6. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007; 130:456-469.

7. Mizokami A, Yasutake Y, Gao J, Matsuda M, Takahashi I, Takeuchi H et al. Osteocalcin induces release of glucagon-like peptide-1 and thereby stimulates insulin secretion in mice. PLoS One. 2013; 8:e57375.

8. Mizokami A, Yasutake Y, Higashi A, Kawakubo-Yasukochi T, Chisaki S, Takahashi I et al. Oral administration of osteocalcin improves glucose utilization by stimulating glucagon-like peptide-1 secretion. Bone. 2014; 69:68-79.

9. Kawakubo-Yasukochi T, Kondo A, Mizokami A, Hayashi Y, Chisaki S, Nakamura S et al. Maternal oral administration of osteocalcin protects offspring from metabolic impairment in adulthood. Obesity. 2016; 24:895-907.

10. Ota K, Mizokami A, Hayashi Y, Gao J, Mori Y, Nakamura S et al. Signaling pathway for adiponectin expression in adipocytes by osteocalcin. Cell Signal. 2015; 27:332-344.

11. Lemmon MA and Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010; 141:1117-1134.

12. Fang G, Zhang Y, Ressler SJ, Ittmann MM, Ayala GE, Dang TD et al. FGFR1 is essential for prostate cancer progression and metastasis. Cancer Res. 2013; 73:3716-3724.

13. Batson J, Maccarthy-Morrough L, Archer A, Tanton H, Nobes CD. EphA receptors regulate prostate cancer cell dissemination through Vav2-RhoA mediated cell-cell repulsion. Biol Open. 2014; 3:453-462.

14. Guan M, Xu C, Zhang F, Ye C. aberrant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features. Int J Cancer. 2009; 124:88-94.

15. Nagano K, Yamashita T, Inoue M, Higashisaka K, Yoshihisa Y, Abe Y et al. Eph receptor A10 has a potential as a target for a prostate cancer therapy. Biochem Biophys Res Commun. 2014; 450:545-549.

16. Kittles RA, Baffoe-Bonnie AB, Moses TY, Robbins CM, Ahabgouto C, Huusko P et al. A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history. J Med Genet. 2006; 43:507-511.

17. Mertens-Walker I, Fernando DC, Maharaj M, Rockstroh A, Nelson CC, Herlington AC et al. The tumour-promoting receptor tyrosine kinase, EphB4, regulates expression of integrin-j8 in prostate cancer cells. BMC Cancer. 2015; 15:164.

18. Linde JE, Mertens-Walker L, Rutkowski R, Herlington AC, Stephenson SA. Eph receptors and their ligands: Promising molecular biomarkers and therapeutic targets in prostate cancer. Biochim Biophys Acta. 2013; 1835:243-257.

19. Barreca A, Lasorsa E, Riera L, Machirollati R, Piva R, Ponzoni M et al. Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol. 2011; 47:811-823.

20. Leung YK, Gao Y, Lau KM, Zhang X, Ho SM. IC1 182,780-regulated gene expression in DU145 prostate cancer cells is mediated by estrogen receptor-beta/NFkappaB crosstalk. Neoplasia. 2006; 8:242-249.

21. Cecchi F, Rabe DC, Bottero DP. Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012; 16:553-572.

22. Hennandez S, de Muga S, Agell L, Juanpere N, Esrua E, Lorente JA et al. FGFR3 mutations in prostate cancer: association with low-grade tumors. Mod Pathol. 2009; 22:848-856.

23. Dawson DM, Lawrence EG, MacLennan GT, Amini SB, Kung HJ, Robinson D et al. Altered expression of RET proto-oncogene product in prostatic intraepithelial neoplasia and prostate cancer. J Natl Cancer Inst. 1998; 90:519-523.

24. Rebagyi G, Van S, Liu C, Cheung NK. ROR1 and ROR2 in human malignancies: potentials for targeted therapy. Front Oncol. 2012; 2:34.

25. Pacece JD, Vogelsang M, Parker MI, Zerbini LF. The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications. Int J Cancer. 2014; 134:2014-2033.

26. Liu Q, Jermigan D, Zhang Y, Fatatis A. Implication of platelet-derived growth factor alpha in prostate cancer skeletal metastasis. Chin J Cancer. 2011; 2011:812-819.

27. Mohamed ER, Noguchi M, Hamed AR, Elahboushary ZM, Hammady AR, Salem EE et al. Reduced expression of erythropoietin-producing hepatocyte B6 receptor tyrosine kinase in prostate cancer. Oncol Lett. 2015; 9:1672-1676.

28. Huang Y, Hamana T, Liu J, Wang C, An L, You P et al. Type 2 fibroblast growth factor receptor signaling preserves stemness and prevents differentiation of prostate stem cells from the basal compartment. J Biol Chem. 2015; 290:17733-17761.

29. Valiathan RR, Marco M, Leitinger B, Kleer CG, Fridman R. Discoidin domain receptor tyrosine kinases: new players in cancer progression. Cancer Metastasis Rev. 2012; 31:295-321.

30. Goodyear SM, Kheyfets SB, Garcia FU, Stearns ME. Role of the VEGFR3/VEGFD receptor axis in TGFbeta1 activation of primary prostate cell lines. Prostate. 2009; 69:982-990.

31. Morrissey C, Dowell A, Koreckij TD, Nguyen H, Lakely B, Fanslow WC et al. Inhibition of angiopoietin-2 in LuCap 23.1 prostate cancer tumors decreases tumor growth and viability. Prostate. 2010; 70:1799-1808.

32. Festuccia C, Cravina GL, Muzi P, Millimaggi D, Dolo V, Vicentini C et al. Her2 crosstalks with TrkA in a subset of prostate cancer cells: rationale for a guided dual treatment. Prostate. 2009; 69:337-345.

http://www.jcancer.org